|
| Anaesthetics | Effects | Summary |
|
| Rocuronium | Rocuronium bromide promotes the proliferation, migration, and invasion of breast cancer cell line MDA-MB-231. Rocuronium can promote the growth, invasion, and migration of gastric cancer cells SGC7901 and BGC823. | Use with caution in patients with breast and stomach cancer |
| Cisatracurium | Cisatracurium enhances TRAIL-induced apoptosis in gastric cancer cells via p53 signaling. Cisatracurium inhibits proliferation, migration, and invasion of breast cancer MDA-MB-231 cells. Cisatracurium regulates the CXCR4/let-7a-5p axis by inhibiting the TGF-β/SMAD2/3 signaling pathway and inhibits colorectal cancer progression by altering the p53-dependent apoptotic pathway and delaying cell migration and invasion by upregulating p53, thereby inhibiting survival, metastasis, and tumor growth. | It is recommended for patients with ovarian, breast, lung, rectal, and gastric cancers |
| Atracurium | Atracurium besylate promotes astrocyte differentiation and depletes glioblastoma stem cells. Atracurium gradually decreases the cell proliferation of hepatoma HepG2 cells in a concentration-dependent manner. | Recommended for patients with glioblastoma and hepatocellular carcinoma |
| Vecuronium | Vecuronium bromide promotes adhesion of gastric cancer cells, inhibits proliferation and metastasis of non-small-cell lung cancer A549 cells, and has little effect on breast cancer cells. | Can be used in breast cancer and non-small-cell lung cancer, but used with caution in gastric cancer |
| Pancuronium | Patients with supratentorial tumors treated with pancuronium have significantly greater increases in intracranial pressure and cardiovascular parameters. | Use with caution in patients with supratentorial tumors |
| Pipecuronium | Pipecuronium provides significantly greater cardiovascular stability and less elevation of intracranial pressure during and for the first 30 minutes after intubation. | Suitable for use in patients with intracranial tumors |
| Tubocurarine | Tubocurarine blocks the stimulating effect of pilocarpine on prostate cancer proliferation. Tubocurarine blocks acetylcholine- (ACh-) induced currents (IACh) in pheochromocytoma cells (PC12 cells). | Suitable for use in patients with prostate cancer and pheochromocytoma |
|
